Statement of retraction: El Fakih, R.O., Champlin, R., Oran, B., 5-Azacitidine for treating acute myelogenous leukemia. Expert Opinion on Orphan Drugs 2015; 3 (10) 1197–1207, DOI: 10.1517/21678707.2015.1089168
The Editor and Publisher regret to announce that the article ‘5-Azacitidine for treating acute myelogenous leukemia’ by Riad O El Fakih et al (Expert Opin Orphan Drugs 2015; 3 (10) 1197–1207) has been retracted by the publisher. The paper was retracted after a report by CrossCheck, plagiarism detection software, identified significant duplication of the following previously published material.
Wang, E.S. Treating acute myeloid leukemia in older adults. ASH Education Book, 2014; 1 14–20
Erba, H.P. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leukemia Research 2015; 39 (2) 183–191
Kaminskas, E. et al. Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes. Clinical Cancer Research 2005 15; 11 (10) 3604–3608
Fenaux, P. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 2009; 10 (3) 223–32
Itzukson, R. et al. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leukemia Research 2015; 39 (2) 124–130
Raj, K. and Mufti, G.j. Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes. Therapeutics and Clinical Risk Management 2006; 2 (4) 377–388.
Platzbecker, U. et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26 (3) 381–389
Wei, A. et al. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia. British Journal of Haematology; 169 (2) 199–210
Jabbour, E. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer; 115 (9) 1899–1905
Expert Opinion on Orphan Drugs published this article in good faith, and on the basis of signed statements made by the corresponding author regarding the originality of this work. The article has been retracted from the journal.
Ian Phillips (Editor in Chief, Expert Opinion on Orphan Drugs)
Elizabeth Knowles (Publisher, Taylor & Francis)